Cargando…
Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215653/ https://www.ncbi.nlm.nih.gov/pubmed/34164334 http://dx.doi.org/10.3389/fonc.2021.622742 |
_version_ | 1783710282986553344 |
---|---|
author | Tsutani, Yasuhiro Shimada, Yoshihisa Ito, Hiroyuki Miyata, Yoshihiro Ikeda, Norihiko Nakayama, Haruhiko Okada, Morihito |
author_facet | Tsutani, Yasuhiro Shimada, Yoshihisa Ito, Hiroyuki Miyata, Yoshihiro Ikeda, Norihiko Nakayama, Haruhiko Okada, Morihito |
author_sort | Tsutani, Yasuhiro |
collection | PubMed |
description | OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8(th) edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS. RESULTS: A multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001). CONCLUSIONS: In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence. |
format | Online Article Text |
id | pubmed-8215653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82156532021-06-22 Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer Tsutani, Yasuhiro Shimada, Yoshihisa Ito, Hiroyuki Miyata, Yoshihiro Ikeda, Norihiko Nakayama, Haruhiko Okada, Morihito Front Oncol Oncology OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8(th) edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS. RESULTS: A multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001). CONCLUSIONS: In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215653/ /pubmed/34164334 http://dx.doi.org/10.3389/fonc.2021.622742 Text en Copyright © 2021 Tsutani, Shimada, Ito, Miyata, Ikeda, Nakayama and Okada https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tsutani, Yasuhiro Shimada, Yoshihisa Ito, Hiroyuki Miyata, Yoshihiro Ikeda, Norihiko Nakayama, Haruhiko Okada, Morihito Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title | Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title_full | Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title_fullStr | Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title_full_unstemmed | Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title_short | Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer |
title_sort | identification of high-risk of recurrence in clinical stage i non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215653/ https://www.ncbi.nlm.nih.gov/pubmed/34164334 http://dx.doi.org/10.3389/fonc.2021.622742 |
work_keys_str_mv | AT tsutaniyasuhiro identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT shimadayoshihisa identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT itohiroyuki identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT miyatayoshihiro identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT ikedanorihiko identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT nakayamaharuhiko identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer AT okadamorihito identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer |